comprehensive -WSS

comprehensive

author：fashion 2025-09-29 13:46:11 - browse：168

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： VC firm General Catalyst wants to buy a health system

WSS

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Bristol 'take

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

AI can decode, harness the power of the humane immune system

Was Amgen transparent enough on FDA's concern on cancer drug?

Sana to lay off nearly a third of staff, de

leisure time

comprehensive

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Assistant physicians can help address the primary care shortage

Drug repurposing or repositioning? The language matters

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

23andMe had bad news about my health. I wish a person had delivered it

Transgender sports debate: Physicians say bans are health issue

Virginia high school admissions case could be legal follow

Why age limits for politicians are a terrible idea

Hepatitis C has a cure — but many Americans still lack access to it

Histogen: Failed biotech offers rare public look inside

focus

Was Amgen transparent enough on FDA's concern on cancer drug?

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Sana to lay off nearly a third of staff, de

Was Amgen transparent enough on FDA's concern on cancer drug?

Senate panel eyes new effort on drug shortages

Sana to lay off nearly a third of staff, de

hotspot

leisure time

hotspot

hotspot